Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Acta Paediatr ; 112(5): 1049-1055, 2023 05.
Artículo en Inglés | MEDLINE | ID: covidwho-2301196

RESUMEN

AIM: Human bocavirus 1 (HBoV1) has been associated with respiratory tract infections in children. We aimed at retrospectively describing patient characteristics, seasonality, pre-existing medical conditions, codetections, clinical manifestations and complications of HBoV1 infection in relation to viral load in the child population in Stockholm, with the overarching aim of elucidating the clinical significance of HBoV1. METHODS: We included all hospitalised children 0-17 years testing positive for HBoV1 by real-time polymerase chain reaction on nasopharyngeal aspirates 1 July 2008-30 June 2019. Patients with HBoV1 single detection, high viral load expressed as an HBoV1-DNA cycle threshold (Ct) < 25, or both, were separately analysed. We retrieved information on pre-existing conditions and clinical course from the medical records. RESULTS: We found 768 episodes in 727 children, 496 (64.6%) male and 441 (60.7%) previously healthy. The median age was 17.6 months. Most (476/768, 62.0%) episodes occurred during December-March. HBoV1 was in 549 episodes (71.5%) codetected with other viruses. Ct < 25 was independently associated with young age, single detection of HBoV1 and presentation early in the epidemic season. We saw few differences in clinical manifestations between the subgroups. CONCLUSION: Our findings are consistent with primary HBoV1 infection causing mild-to-severe respiratory tract manifestations in young children.


Asunto(s)
Bocavirus Humano , Infecciones por Parvoviridae , Infecciones del Sistema Respiratorio , Humanos , Niño , Masculino , Lactante , Preescolar , Femenino , Bocavirus Humano/genética , Estudios Retrospectivos , Infecciones por Parvoviridae/diagnóstico , Infecciones por Parvoviridae/epidemiología , Infecciones del Sistema Respiratorio/diagnóstico , Infecciones del Sistema Respiratorio/epidemiología , Reacción en Cadena en Tiempo Real de la Polimerasa
2.
Transfus Med ; 32(5): 402-409, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: covidwho-1909541

RESUMEN

BACKGROUND AND OBJECTIVES: Infections with human parvovirus B19 (B19V) are transmissible by blood components and plasma-derived medicines. The European Pharmacopoeia regulates maximum levels of virus allowed in manufacturers' plasma pools. To evaluate contamination risk prior to re-introduction of UK-sourced plasma for manufacturing, we investigated viraemia frequencies of B19V in plasma samples collected from blood donors before and during COVID-enforced lockdown. MATERIALS AND METHODS: Quantitative PCR for B19V DNA was used to screen pools of 96 anonymised plasma samples collected in England from 2017 (n = 29 505), 2020 (n = 3360) and 2021 (n = 43 200). Selected positive pools were resolved into individual samples. Data on donor notifications and related lookback investigations were collected from European countries by on-line survey in 2020. RESULTS: Screening of 76 065 donations identified 80 B19V-positive pools. While most positive samples had low viral loads (<105  IU ml-1 ), primarily from 2017 (77/29 505; 0.3%), two contained high levels of B19V DNA (1.3 × 108 and 6.3 × 106 IU ml-1 ), both likely to contaminate a final manufacturer's pool and lead to discard. The incidence of B19V infection during lockdown was reduced (1/3360 in 2020; 0/43 200 in 2021). Genomic analysis of positive pools resolved to single samples identified B19V genotype 1 in all nine samples. Seroprevalence of anti-B19V IgG antibodies was 75% (143/192). A survey of B19V screening practices in Europe demonstrated considerable variability. Two blood establishments informed infected blood donors of positive B19V results. CONCLUSION: Information on seroprevalence, incidence and viral loads of B19V viraemia is contributory the evaluation of alternative operational screening strategies for plasma testing.


Asunto(s)
COVID-19 , Infecciones por Parvoviridae , Parvovirus B19 Humano , Anticuerpos Antivirales , Donantes de Sangre , Control de Enfermedades Transmisibles , ADN Viral , Humanos , Inmunoglobulina G , Infecciones por Parvoviridae/epidemiología , Parvovirus B19 Humano/genética , Estudios Seroepidemiológicos , Carga Viral , Viremia/epidemiología
3.
Arch Virol ; 167(9): 1831-1840, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: covidwho-1899185

RESUMEN

Viral enteritis is a significant threat to domestic dogs. The two primary pathogens that cause viral enteritis in dogs are canine coronavirus (CCoV) and canine parvovirus (CPV). In this study, we investigated the occurrence of CPV-2, CCoV, and canine circovirus coinfection by characterizing circulating subtypes of CPV-2 in faecal samples from symptomatic dogs admitted to veterinary clinics located in Ankara, Elazig, Kayseri, and Kocaeli provinces of Turkey, between 2019 and 2022. Virus detection by PCR and RT-PCR revealed that CPV-2 was present in 48 (77.4%) samples, and no other agents were detected. Based on the occurrence of the codon GAT at positions 1276 to 1278 (coding for aspartate at residue 426) of VP2, all CPV-2 isolates were confirmed to be of the CPV-2b subtype. The complete genome sequences of two CPV-2b isolates showed a high degree of similarity to and phylogenetic clustering with Australian and East Asian strains/isolates. The predominant CPV strain circulating in the three different regions of Turkey was found to be a CPV-2b strain containing the amino acid substitutions at Y324I and T440A, which commonly contribute to immune escape. This is the first report of complete genomic analysis of CPV-2 isolates circulating in symptomatic domestic dogs in Turkey. The evolution of CPV-2 has raised questions about the efficacy of current vaccination regimes and highlights the importance of monitoring the emergence and spread of new CPV-2 variants.


Asunto(s)
Coronavirus Canino , Enfermedades de los Perros , Enteritis , Infecciones por Parvoviridae , Parvovirus Canino , Animales , Australia , Enfermedades de los Perros/epidemiología , Perros , Genómica , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/veterinaria , Filogenia , Turquia/epidemiología
5.
Viruses ; 12(12)2020 12 10.
Artículo en Inglés | MEDLINE | ID: covidwho-967102

RESUMEN

Previous work has indicated that canine parvovirus (CPV) prevalence in the Central Texas region may follow yearly, periodic patterns. The peak in CPV infection rates occurs during the summer months of May and June, marking a distinct "CPV season". We hypothesized that human activity contributes to these seasonal changes in CPV infections. The COVID-19 pandemic resulted in drastic changes in human behavior which happened to synchronize with the CPV season in Central Texas, providing a unique opportunity with which to assess whether these society-level behavioral changes result in appreciable changes in CPV patient populations in the largest CPV treatment facility in Texas. In this work, we examine the population of CPV-infected patients at a large, dedicated CPV treatment clinic in Texas (having treated more than 5000 CPV-positive dogs in the last decade) and demonstrate that societal-behavioral changes due to COVID-19 were associated with a drastic reduction in CPV infections. This reduction occurred precisely when CPV season would typically begin, during the period immediately following state-wide "reopening" of business and facilities, resulting in a change in the typical CPV season when compared with previous years. These results provide evidence that changes in human activity may, in some way, contribute to changes in rates of CPV infection in the Central Texas region.


Asunto(s)
COVID-19/epidemiología , Enfermedades de los Perros/epidemiología , Infecciones por Parvoviridae/veterinaria , Animales , COVID-19/prevención & control , Control de Enfermedades Transmisibles/legislación & jurisprudencia , Enfermedades de los Perros/terapia , Perros , Hospitales Veterinarios , Humanos , Unidades de Cuidados Intensivos , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/terapia , Parvovirus Canino/patogenicidad , Prevalencia , Política Pública , SARS-CoV-2 , Texas/epidemiología
6.
Prev Vet Med ; 174: 104817, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: covidwho-826992

RESUMEN

Canine Parvovirus (CPV) causes severe morbidity and mortality in dogs, particularly puppies, worldwide. Although vaccination is highly efficacious in preventing disease, cases continue to occur and vaccination failures are well documented. Maternally derived antibody interference is the leading cause of vaccination failure and age at vaccine administration is a significant risk factor for failure. However, no studies have been performed on practicing veterinarians' usage of and compliance with published vaccination guidelines and label recommendations. Likewise, there are no published studies of veterinarian perceptions on CPV occurrence and mortality and its influence on case outcome. We report a study in which all Australian small companion animal (canine and feline) veterinary hospitals were surveyed, yielding a response rate of 23.5% (534 unique veterinary hospitals). Respondents overall perceived national CPV occurrence ten-times lower (median 2000 cases) than the estimated national caseload (20,000 cases). Respondents from hospitals that did not diagnose CPV perceived national occurrence twenty-times lower (median 1000 cases) than the estimated rate (p < 0.0001). Perceived disease mortality (50%) was 2.74 times higher than that reported (18.2%). In addition, 26.7% of veterinarians reported using serological titer testing to some degree, which some practitioners use in lieu of vaccination if a titer is perceived to reflect sufficient immunity. Based on this study veterinarians appear to be aware of the disease risk in their region but unaware of the burden of CPV disease nationally, and perceive mortality risk higher than it actually is. This might lead to an overestimation of cost to treat, and over-recommendation of euthanasia. Nearly half (48.7%) of respondents recommended final puppy vaccination earlier than guidelines recommend, while 2.8% of respondents recommended a puppy re-vaccination interval longer than supported by vaccine labels and guidelines. Both of these practices may put puppies at risk of CPV infection.


Asunto(s)
Control de Enfermedades Transmisibles , Enfermedades de los Perros/psicología , Conocimientos, Actitudes y Práctica en Salud , Infecciones por Parvoviridae/veterinaria , Parvovirus Canino , Veterinarios/psicología , Animales , Australia/epidemiología , Enfermedades de los Perros/epidemiología , Enfermedades de los Perros/prevención & control , Perros , Mortalidad , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/prevención & control , Infecciones por Parvoviridae/psicología , Prevalencia
7.
World J Pediatr ; 16(3): 293-298, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: covidwho-617249

RESUMEN

BACKGROUND: The role of human bocavirus (HBoV) as a respiratory pathogen has not been fulfilled yet. We aimed to describe clinical and serological characteristics of children with HBoV hospitalized for acute respiratory tract infection and to evaluate whether differences occur between HBoV alone and in co-infection. METHODS: We retrospectively reviewed data from 60 children (median age of 6.2 months, range 0.6-70.9) hospitalized for acute respiratory symptoms, with HBoV detected from a respiratory sample, using a reverse transcriptase-PCR for 14 respiratory viruses (including respiratory syncytial virus (RSV), influenza virus A and B, human coronavirus OC43, 229E, NL-63 and HUK1, adenovirus, rhinovirus, parainfluenza virus1-3, and human metapneumovirus). RESULTS: HBoV was detected alone in 29 (48.3%) patients, while in co-infection with other viruses in 31 patients (51.7%), with a peak between December and January. Among the 60 patients, 34 were bronchiolitis, 19 wheezing, 3 pneumonia, 2 upper respiratory tract infection, and 2 whooping cough. Seven children (11.6%) required admission to the paediatric intensive care unit (PICU) for respiratory failure. No differences was observed in age, family history for atopy and/or asthma, clinical presentations, chest X-ray, or laboratory findings in children with HBoV alone vs. multiple viral detection. RSV was the most frequently co-detected virus (61.3%). When compared with HBoV detection alone, the co-detection of RSV and HBoV was associated with male sex (P = 0.013), younger age (P = 0.01), and lower blood neutrophil count (P = 0.032). CONCLUSIONS: HBoV can be detected alone and in co-infection respiratory samples of children with an acute respiratory tract infection. A cause-effect relationship between HBoV and respiratory infection is not clear, so further studies are needed to clarify this point.


Asunto(s)
Hospitalización/estadística & datos numéricos , Bocavirus Humano/aislamiento & purificación , Infecciones por Parvoviridae/diagnóstico , Infecciones del Sistema Respiratorio/virología , Enfermedad Aguda , Distribución por Edad , Niño , Preescolar , Coinfección/epidemiología , Coinfección/virología , Bases de Datos Factuales , Servicio de Urgencia en Hospital , Femenino , Hospitales Universitarios , Humanos , Incidencia , Lactante , Unidades de Cuidado Intensivo Pediátrico , Italia , Masculino , Infecciones por Parvoviridae/epidemiología , Pronóstico , Infecciones del Sistema Respiratorio/diagnóstico , Infecciones del Sistema Respiratorio/epidemiología , Estudios Retrospectivos , Ciudad de Roma , Índice de Severidad de la Enfermedad , Distribución por Sexo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA